Buspirone monotherapy (0.5 mg/kg daily for 6 weeks) was evaluated in 12 children (10 boys, 2 girls), aged 6 to 12 years, with ADHD at the Maudsley Hospital, London, UK. Compared to baseline scores on Conners Parent and other rating scales, all 12 patients showed significant improvements in hyperactivity, impulsivity, inattention, and disruptive behavior. Behaviors resumed on discontinuing Buspirone after 6 weeks. Mild dizziness occurred in 2 in the first week. [1]

COMMENT. Controlled trials of buspirone in larger samples of ADHD children seem justified. Buspirone is reported to increase noradrenergic and dopaminergic output, while modulating the serotonergic system. Used previously in children with anxiety, buspirone was tried in ADHD because of low toxicity and twice-daily regimen, not interfering with school schedules. All four dimensions of attention, hyperactivity, impulsivity, and behavioral problems improved, without rebound worsening of symptoms or development of tolerance. Effects on cognitive function need to be addressed, using psychological testing and teacher rating scales.